Zenas BioPharma (ZBIO) is up 10.6%, or $3.45 to $36.04.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside
- Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential
- Zenas BioPharma Approves 2026 Inducement Plan
- Zenas BioPharma falls -13.0%
- InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib